AE	adverse event
ccRCC	clear cell renal cell carcinoma
eNOS	endothelial nitric oxide synthase
FDA	food and drug administration
HUVEC	human umbilical vein endothelial cells
IGF-1	insulin-like growth factor type 1
MTD	maximum tolerated dose
mRCC	metastatic renal cell carcinoma
mTOR	mammalian target of rapamycin
mTORC1	mammalian target of rapamycin complex 1
mTORC2	mammalian target of rapamycin complex 2
NO	nitric oxide
NOS	nitric oxide synthase
OS	overall survival
PFS	progression free survival
pVHL	von Hippel-Lindau protein
RCC	renal cell carcinoma
RCT	randomized controlled trial
RTK	receptor tyrosine kinase
TNM	cancer staging classification based on tumor/nodes/metastases
VEGF	vascular endothelial growth factor
VEGFR1	vascular endothelial growth factor receptor 1
VEGFR2	vascular endothelial growth factor receptor 2
VEGFR3	vascular endothelial growth factor receptor 3
VHL	von Hippel-Lindau